Hemic Or Immune System (e.g., Hematopoietic System, Bone Marrow Cells, Etc.) Patents (Class 424/577)
-
Publication number: 20080131509Abstract: Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.Type: ApplicationFiled: December 4, 2006Publication date: June 5, 2008Inventors: Syed Hossainy, Michael Ngo, Mikael Trollsas, John Stankus, Gene Michal
-
Patent number: 7309501Abstract: Conditioned media compositions having valuable biological activity are obtained from cultures of immune cells from elasmobranch fishes. A method is provided for producing the conditioned media compositions. Conditioned media obtained using epigonal cells from bonnethead sharks (Sphyrna tiburo) and lemon sharks (Negaprion brevirostris) demonstrate strong anti-tumor activities. The conditioned media compositions can be used for treating tumor proliferation.Type: GrantFiled: May 19, 2005Date of Patent: December 18, 2007Assignee: Mote Marine LaboratoryInventors: Catherine J. Walsh, Carl A. Luer
-
Patent number: 7303769Abstract: There is provided an isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), a method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures, and characterization of and uses, particularly therapeutic uses for such cells. Specifically, there is provided isolated MPCs which can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.Type: GrantFiled: February 10, 2005Date of Patent: December 4, 2007Assignee: University of South FloridaInventor: Beerelli Seshi
-
Patent number: 7294331Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and methods of using Flt3-ligand in hematopoietic cell transplantation.Type: GrantFiled: December 5, 2002Date of Patent: November 13, 2007Assignee: Immunex CorporationInventors: Stewart D. Lyman, M. Patricia Beckmann
-
Patent number: 7282222Abstract: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the bone marrow or from umbilical cord tissue. The methods are also useful for targeting a gene of interest to a tissue in a mammal by introducing a cell containing the gene of interest and administering a glycoconjugate to the mammal.Type: GrantFiled: March 14, 2003Date of Patent: October 16, 2007Assignee: The United States of America as Represented by the Department of Veterans AffairsInventor: Catherine Phillips
-
Patent number: 7282201Abstract: This invention has as its object providing promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors which are useful as therapeutics of diseases that result from insufficient growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors, in particular, as therapeutics of panhematopenia and/or diseases that are accompanied by hematopoietic hypofunction. The invention attains the stated object by providing promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors that contain Cofilin as an active ingredient.Type: GrantFiled: August 28, 2003Date of Patent: October 16, 2007Assignee: Asubio Pharma Co., Ltd.Inventors: Kenju Miura, Munetada Haruyama, Shiho Kodama
-
Patent number: 7232566Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: January 4, 2005Date of Patent: June 19, 2007Assignees: The United States as represented by the Secretary of the Navy, The Regents of the University of Michigan, Genetics Institute, LLCInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 7211258Abstract: The invention provides methods for modulating an immune response in a subject including, for example, administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor sufficient to modulate the immune response. In one aspect, the lymphocyte differentiation factor comprises protein A (PA).Type: GrantFiled: April 10, 2002Date of Patent: May 1, 2007Assignee: Protalex, Inc.Inventor: Paul Mann
-
Patent number: 7195758Abstract: We teach a strategy to obtain large quantities of desired APCs, activated B cells, which are superior in their capacity to present tumor protein antigen in a multiadministration protocol. Human B cells can be obtained from peripheral blood in large numbers. These cells can be activated in vitro by coculture with CD40L (CD40-B cells) and an immunosuppressive agent such as cyclosporin A. They can expanded up to 1×103 to 1×104 fold in 2 weeks or 1×105 to 1×106 fold in 2 months. We demonstrate these cells are most efficient APCs comparable to DCs in stimulating allogeneic CD4+ CD45RA+, CD4+ CD45RO+, and CD8+ T cells. In contrast to DCs, CD40-B cells are fully functional even in the presence of immunosuppressive cytokines such as IL-10 and TGF?.Type: GrantFiled: July 1, 2002Date of Patent: March 27, 2007Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Joachim L. Schultze, Gordon J. Freeman, John G. Gribben, Lee M. Nadler
-
Patent number: 7175843Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: March 2, 2006Date of Patent: February 13, 2007Assignees: Genetics Institute, LLC, Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 7144575Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: March 17, 2003Date of Patent: December 5, 2006Assignees: The Regents of the University of Michigan, Genetics Institute, LLC, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 7138144Abstract: A method of inducing tolerance to a transplant transplanted from a donor to a subject is disclosed. The method comprises (a) restricting outflow of a fluid from a portion of the circulatory system of the subject; and (b) administering a dose of bone marrow cells derived from the donor to a body part delimiting said portion of the circulatory system, prior to, concomitantly with or following transplantation of the transplant, thereby inducing tolerance to the transplant in the subject.Type: GrantFiled: September 9, 2002Date of Patent: November 21, 2006Inventor: Nadir Askenasy
-
Patent number: 7129070Abstract: A method is presented for killing a first population of cells within a mixture of viable cells by providing the mixture of viable cells, contacting the cells with a label, illuminating a portion of the mixture, capturing an image of multiple cells in the illuminated portion of the mixture, determining at least two dimensional coordinates of one or more cells of the first population of cells using the first captured image, and applying a lethal dose of energy to said dimensional coordinates of the one or more cells at a first focal plane.Type: GrantFiled: January 9, 2003Date of Patent: October 31, 2006Assignee: Cyntellect, Inc.Inventor: Bernhard O. Palsson
-
Patent number: 7122178Abstract: A method of enriching mesenchymal precursor sells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilizing MACS recognizing expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilizing two color FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.Type: GrantFiled: July 7, 2000Date of Patent: October 17, 2006Assignee: Angioblast Systems, IncorporatedInventors: Paul Simmons, Andrew Zannettino, Stan Gronthos
-
Patent number: 7029671Abstract: The invention relates to a method for activating human-derived antigen-presenting cells by in vitro cultivation with at least one of the glycoside compounds represented by formula (A) or salts thereof [preferred example: (2S,3S,4R)-1-(?-D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol], and to human antigen-presenting cells activated by the method. The invention also relates to a method for treatment of cancer and infectious diseases including AIDS with the activated human antigen-presenting cells, and to a use of the activated human antigen-presenting cells in the preparation of medicines for treating such diseases. The invention can provide a satisfactory therapeutic effect on cancer and infectious diseases including AIDS without the need to pulse the human antigen-presenting cells with tumor antigens.Type: GrantFiled: November 27, 2000Date of Patent: April 18, 2006Assignee: Kirin Brewery Company, LimitedInventors: Yasuhiko Koezuka, Yasunori Yamaguchi, Kazuhiro Motoki
-
Patent number: 6984383Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.Type: GrantFiled: July 27, 2000Date of Patent: January 10, 2006Assignee: Genetics Institute, LLCInventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
-
Patent number: 6977073Abstract: A method is described whereby dendritic cells derived from the CD34+ and CD 34?hematopoietic cell lineages are directed to become programmable antigen presenting cells. The programmed cells may be pulsed with tumor cell RNA or tumor cell RNA expression products. The protocol provides for directing the maturation of dendritic cells to become antigen presenting cells. The protocol further provides for isolating tumor cell RNA from biopsy material that has been prepared in paraffin block storage. The directed dendritic cell is provided with a plurality of tumor markers by using tumor RNA in toto, the poly A+RNA fraction or the expression product of such RNA. Once activated the dendritic cells are incubated with T4 and T8 lymphocytes to stimulate and sensitize the T lymphocytes which upon introduction either into a donor host or a nondonor recipient will provide immune response protection.Type: GrantFiled: November 10, 2003Date of Patent: December 20, 2005Inventors: Cem Cezayirli, Mel Silvers
-
Patent number: 6967029Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.Type: GrantFiled: August 21, 2000Date of Patent: November 22, 2005Assignee: Amgen Inc.Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
-
Patent number: 6962698Abstract: A method of expanding a population of cells, while at the same time inhibiting differentiation of the cells, the method includes the step of providing the cells with conditions for cell proliferation and, at the same time, for reducing a capacity of the cells in utilizing cooper. The method can be executed both in-vivo and ex-vivo. A method of inducing differentiation in a population of cells, the method includes the step of providing the cells with a transition metal chelator which binds copper and which is effective in inducing cell differentiation.Type: GrantFiled: August 17, 1999Date of Patent: November 8, 2005Assignees: Gamida Cell Ltd., Hadasit Medical Research Services and Development, Ltd.Inventors: Tony Peled, Eitan Fibach, Avi Treves
-
Patent number: 6953576Abstract: Novel cells and molecules involved in tumor immunity are disclosed. The novel cells are regulatory T-cells having the phenotype CD3+??-TcR+CD4?CD8?CD44?CD28?NK1.1?. The regulatory cells express Ly6A and osteopontin while non-regulatory cells do not.Type: GrantFiled: August 21, 2001Date of Patent: October 11, 2005Assignee: University Health NetworkInventors: Li Zhang, Kevin Young
-
Patent number: 6936281Abstract: There is provided an isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), a method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures, and characterization of and uses, particularly therapeutic uses for such cells. Specifically, there is provided isolated MPCs which can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.Type: GrantFiled: May 21, 2001Date of Patent: August 30, 2005Assignee: University of South FloridaInventor: Beerelli Seshi
-
Patent number: 6905680Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: January 26, 1996Date of Patent: June 14, 2005Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 6905681Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: July 8, 1999Date of Patent: June 14, 2005Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 6887466Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: July 8, 1999Date of Patent: May 3, 2005Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 6884413Abstract: The present invention concerns methods of specifically inhibiting an immune response of a subject to one or more selected antigens using an immunosuppressive composition derived from a glioblastoma cell line. The method steps include obtaining a population of antigen presenting cells (APCs); loading the APC population with specific antigens (in auto-immune diseases) or using donor APCs (for transplantation); incubating the APC population with the immunosuppressive composition; and introducing the incubated cells into the subject being treated. The APCs can be monocytes, macrophages, or dendritic cells. This method causes specific inhibition of the immune response because it induces apoptosis and/or anergy in the subject's T cells specific for antigens present on the APCs, but does not affect the immune response to antigens not present on the APC surfaces.Type: GrantFiled: March 23, 2000Date of Patent: April 26, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Gene M. Shearer, Jian-Ping Zuo, John E. Coligan, Claire Chougnet
-
Patent number: 6875430Abstract: A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.Type: GrantFiled: November 13, 2001Date of Patent: April 5, 2005Assignee: Osiris Therapeutics, Inc.Inventors: Kevin R. McIntosh, Joseph D. Mosca, Elena Klyushnenkova
-
Patent number: 6733791Abstract: Methods and compositions are described which allow for the sublingual absorption of peptides by oral administration. A liquid and a tablet format for the sublingual approach are demonstrated. The peptides are stable at room temperature and in the compositions herein described.Type: GrantFiled: July 8, 2002Date of Patent: May 11, 2004Inventor: Morris A. Mann
-
Patent number: 6558662Abstract: The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.Type: GrantFiled: November 13, 1998Date of Patent: May 6, 2003Assignee: The General Hospital CorporationInventors: Megan Sykes, Thomas R. Spitzer
-
Patent number: 6534055Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: May 4, 1995Date of Patent: March 18, 2003Assignee: Genetics Institute, Inc.Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Publication number: 20030026786Abstract: Disclosed are a composition of chemically defined components having elevated levels of simple sugars which support the enhanced in vitro chondrogenesis of mesenchymal progenitor cells, a method for in vitro chondrogenic induction of such progenitor cells and a method of forming human chondrocytes in vitro from such progenitor cells.Type: ApplicationFiled: June 4, 1999Publication date: February 6, 2003Inventors: MARK F. PITTENGER, ALASTAIR M. MACKAY, J. MARY MURPHY, FRANCIS P. BARRY
-
Patent number: 6497876Abstract: Antigen-expressing, activated dendritic cells are disclosed. Such dendritic cells are used to present tumor, viral or bacterial antigens to T cells, and can be useful in vaccination protocols. Other cytokines can be used in separate, sequential or simultaneous combination with the activated, antigen-pulsed dendritic cells. Also disclosed are methods for stimulating an immune response using the antigen-expressing, activated dendritic cells.Type: GrantFiled: October 29, 1999Date of Patent: December 24, 2002Assignee: Immunex Corp.Inventors: Eugene Maraskovsky, Hilary J. McKenna
-
Publication number: 20020187135Abstract: Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand on the antigen presenting cell with the receptor on the T cell. In a preferred embodiment, the cell which presents antigen to the T cell is a B cell and the receptor on the surface of the T cell which mediates contact-dependent helper effector function is gp39. Preferably, the antagonist is an anti-gp39 antibody or a soluble gp39 ligand (e.g., soluble CD40). The methods of the invention can be used to induce T cell tolerance to a soluble antigen or to an allogeneic cell.Type: ApplicationFiled: October 1, 1998Publication date: December 12, 2002Inventors: RANDOLPH J. NOELLE, TERESA M. FOY, FIONA H. DURIE
-
Patent number: 6479538Abstract: Novel cyclic ether vitamin D3 compounds having a cyclic ether side chain are disclosed. These compounds were first identified as metabolites of 3-epi vitamin D3 produced via a tissue-specific metabolic pathway which catalyzes the formation of a cyclic ether structure. Also disclosed are 1&agr;(OH) 3-epi vitamin D3 compounds, which are produced via the epimerization of a 3-&bgr;-hydroxyl group of 1&agr;(OH) vitamin D3 precursor in vivo. The vitamin D3 compounds of the present invention can be used as substitutes for natural and synthetic vitamin D3 compounds.Type: GrantFiled: July 17, 2000Date of Patent: November 12, 2002Assignee: Women and Infants HospitalInventor: Satayanarayana G. Reddy
-
Patent number: 6436411Abstract: Treatment of tumors, including their metastases, is described. Retrieved cytokines and other molecules from the growth medium of human monocytes stimulated ex vivo with gamma globulin, or other immune stimulators are employed for cancer therapy.Type: GrantFiled: October 23, 2000Date of Patent: August 20, 2002Assignee: The Center for the Improvement of Human Functioning, Int'l., Inc.Inventors: Neil H. Riordan, Hugh D. Riordan
-
Patent number: 6428950Abstract: The present invention provides a method of assaying for and arresting, preventing and/or reversing the impairment of central and peripheral nervous system function comprising reducing &bgr;-amyloid plaque burden by the administration of compounds that reduce apoE expression. The compounds used in the method of the invention may be: 1) inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase; 2) inhibitors of cholesterol biosynthesis; 3) inhibitors of protein isoprenylation, specifically geranylgeranylation; and/or 4) inhibitors of NF-&kgr;B activation or function. Assays for compounds with inhibit apoE expression from microglial cells are also disclosed.Type: GrantFiled: November 22, 1999Date of Patent: August 6, 2002Assignees: Scios Inc., Eli Lilly & Co.Inventors: Barbara Cordell, Qiang Xu, Asha Naidu, Steven M. Paul, Kelly R. Bales
-
Patent number: 6387369Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.Type: GrantFiled: March 27, 2000Date of Patent: May 14, 2002Assignee: Osiris Therapeutics, Inc.Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
-
Publication number: 20020049404Abstract: The present invention provides a method of inducing systemic tolerance to an antigen in an individual in need of such treatment, comprising the step of: administering antigen presenting cells to said individual, wherein said cells express Fas ligand and said antigen.Type: ApplicationFiled: May 15, 1998Publication date: April 25, 2002Inventors: JOHN D. MOUNTZ, TONG ZHOU
-
Patent number: 6375950Abstract: Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor which inhibits interaction of the ligand with the receptor. In a preferred embodiment, the allogeneic or xenogeneic cell is a B cell, preferably a resting B cell, and the molecule on the surface of the T cell which mediates contact-dependent helper effector function is gp39. A preferred gp39 antagonist is an anti-gp39 antibody. The allogeneic or xenogeneic cell and the gp39 antagonist are typically administered to a transplant recipient prior to transplantation of the tissue or organ.Type: GrantFiled: January 5, 1999Date of Patent: April 23, 2002Assignees: University of Massachusetts Medical Center, Trustees of Dartmouth CollegeInventors: Randolph J. Noelle, Fiona H. Durie
-
Patent number: 6368636Abstract: A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.Type: GrantFiled: October 26, 1999Date of Patent: April 9, 2002Assignee: Osiris Therapeutics, Inc.Inventors: Kevin R. McIntosh, Joseph D. Mosca, Elena N. Klyushnenkova
-
Publication number: 20020037326Abstract: Peptides derived from shark immunoglobulin preparations are used to prepare compositions, including pharmaceutical compositions, for inhibiting retrovirus replication in susceptible cells. The peptide preparations are useful for inhibiting diseases associated with retroviral infection, such as acquired immunodeficiency syndrome. The peptides also inhibit growth of tumor cells, especially sarcomas and leukemias.Type: ApplicationFiled: April 2, 1998Publication date: March 28, 2002Inventor: MARK E. HOWARD
-
Patent number: 6353150Abstract: There is disclosed a chimeric mammal having a stable bone marrow graft of human hematopoietic cells capable of differentiating into multiple lineages of human mature cells, wherein at least 30% of the hematopoietic cells in the mammal's bone marrow are of human origin. The inventive method comprises sublethally irradiating an immunodeficient mammal, infusing human hematopoietic cells into the mammal and administering an effective amount of human mast cell growth factor (MGF) and a human granulocyte macrophage colony stimulating factor/interleukin-3 fusion protein (GM-CSF/IL-3 FP) to promote engraftment of human cells within the chimeric mammal's bone marrow.Type: GrantFiled: November 22, 1991Date of Patent: March 5, 2002Assignee: HSC Research and Development Limited PartnershipInventors: John E. Dick, Douglas E. Williams, Tsvee Lapidot
-
Patent number: 6352694Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: March 10, 1995Date of Patent: March 5, 2002Assignees: Genetics Institute, Inc., The Regents of the University of MichiganInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 6328960Abstract: Disclosed is a method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.Type: GrantFiled: March 12, 1999Date of Patent: December 11, 2001Assignee: Osiris Therapeutics, Inc.Inventors: Kevin R. McIntosh, Joseph D. Mosca, Elena N. Klyushnenkova
-
Publication number: 20010048921Abstract: The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.Type: ApplicationFiled: November 13, 1998Publication date: December 6, 2001Applicant: The General Hospital CorporationInventors: MEGAN SYKES, THOMAS R. SPITZER
-
Patent number: 6312692Abstract: A method of treating graft-vs-host diseases by administration of bone marrow and an anti-gp39 antibody specific to human gp39 is provided.Type: GrantFiled: April 30, 1998Date of Patent: November 6, 2001Assignees: Trustees of Dartmouth College, Bristol-Myers Squibb CompanyInventors: Randolph J. Noelle, Teresa M. Foy, Alejandro Aruffo, Jeffrey A. Ledbetter
-
Patent number: 6296846Abstract: The invention features a method designed to lengthen the time an implanted organ (a xenograft) survives in a xenogeneic host prior to rejection. Preparation of the recipient for transplantation includes the following steps: First, the recipient is administered low dose radiation. Second, an antibody preparation that binds T cells and NK cells is injected into the recipient. Third, natural antibodies are absorbed from the recipient's blood by hemoperfusion of an organ of the donor species. Fourth, hematopoietic stromal tissue of the donor species is administered to the recipient. Fifth, donor hematopoietic stem cells are injected into the recipient. Finally, the xenograft organ is implanted into the recipient mammal. Best results are obtained when all steps are used in combination.Type: GrantFiled: May 26, 1995Date of Patent: October 2, 2001Assignee: The General HospitalInventors: David H. Sachs, A. Benedict Cosimi, Megan Sykes
-
Publication number: 20010014320Abstract: The present invention provides a method of transplanting hematopoietic system reconstituting cells from a donor into an allogeneic recipient comprising administering to the recipient, prior to the administration of the hematopoietic system reconstituting cells, an amount of mononuclear cells which are treated so as to render them incapable of proliferating and causing a lethal graft versus host disease effect, but which are effective in enhancing subsequent engraftment of the hematopoietic system reconstituting cells in the recipient; and administering to the recipient an effective amount of hematopoietic system reconstituting cells.Type: ApplicationFiled: December 22, 2000Publication date: August 16, 2001Applicant: Emory UniversityInventor: Edmund K. Waller
-
Patent number: 6231879Abstract: This invention is directed to methods of manufacturing implantable biocompatible cell encapsulation devices, wherein the cell encapsulation devices have a jacket made of a permeable, biocompatible material that is loaded with a core made of a reticulate foam scaffold having interconnected pores, with cells that are dispersed in the interconnected pores.Type: GrantFiled: February 9, 1999Date of Patent: May 15, 2001Assignee: Neurotech S.A.Inventors: Rebecca Li, Tyrone F. Hazlett
-
Patent number: 6231893Abstract: A novel immunosuppressive factor derived from mammalian bone marrow is described, which inhibits T lymphocyte activation and TNF-&agr; production by activated macrophages and also inhibits tumour and leukemia cell growth. The factor provides a novel therapeutic composition for treatment of tumours and of disorders associated with inflammatory reactions or T lymphocyte activation.Type: GrantFiled: August 1, 1997Date of Patent: May 15, 2001Assignee: London Health Services CentreInventor: Sharwan K. Singhal
-
Patent number: 6190655Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3-L finds use in treating patients with anemia, AIDS and various cancers.Type: GrantFiled: September 25, 1998Date of Patent: February 20, 2001Assignee: Immunex CorporationInventors: Stewart D. Lyman, M. Patricia Beckmann